Kardigan targets up to $1.4 billion valuation in US IPO

Kardigan Inc. is pursuing a US initial public offering to raise $373.3 million. The biotech company intends to use these funds to support the development of three late-stage drugs specifically targeting cardiovascular diseases. Through this IPO process, Kardigan is targeting a company valuation of up to $1.4 billion. The offering aims to provide the necessary capital to advance its heart health pipeline and establish a significant market presence within the United States healthcare sector.